Evidence map›Paper›PMID 41904157›Full record

ArticleNature communications2026

FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment.

Lourdes Brea, Hongshun Shi, Viriya Keo, Jing Huang, Liu Peng, Qi Chu, Wanqing Xie, Yinghua Xie, Sambhavi Senthil, Matthew T Breneman and 11 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Lourdes BreaDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-9727-7185
Hongshun ShiDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Viriya KeoDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Jing HuangDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-9403-9939
Liu PengDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Qi ChuDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Wanqing XieDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Yinghua XieDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Sambhavi SenthilDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Matthew T BrenemanWilliam S. Middleton Memorial Veterans' Hospital, Madison, WI, USA.
Jie FanDivision of Hematology/Oncology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Ping XieDivision of Hematology/Oncology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Xiaodong LuDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-4731-0762
David J DegraffDepartment of Pathology and Laboratory Medicine, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Sarki A AbdulkadirDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID http://orcid.org/0000-0003-2963-2899
Ximing YangDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
David KosoffWilliam S. Middleton Memorial Veterans' Hospital, Madison, WI, USA.
Jonathan C ZhaoDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-3163-380X
Bin ZhangDivision of Hematology/Oncology, Department of Medicine, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-6631-7647
Jian HuDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-2852-7675
Jindan YuDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA. jindan.yu@emory.edu.ORCID http://orcid.org/0000-0002-2326-0409

Funding

Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A. · 2015 to 2025
$19.9M
CARCINOGENESIS TRAINING PROGRAMT32CA009560 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Kathleen Janee Green · 1986 to 2026
$8.4M
Comprehensive Analyses of HOXB13-regulated Transcriptional programs critical for Prostate Cancer ProgressionR01CA257446 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI YU, JINDAN · 2021 to 2025
$2.4M
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1AR01CA275193 · NCI · EMORY UNIVERSITY · PI Jindan Yu, Changsheng Zhao · 2023 to 2026
$2.0M
FOXA1 loss-of-function induces inflammatory cytokine signaling and immune suppression in prostate cancerF31CA271826 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BREA, LOURDES · 2022 to 2023
$85k
CSRD VA I01 CX002479NCI NIH HHS F31 CA271826NCI NIH HHS P50 CA180995NCI NIH HHS R01 CA257446NCI NIH HHS R01 CA275193Prostate Cancer Foundation (PCF) 2017CHAL2008University of Wisconsin Carbone Cancer Center (UW Carbone Cancer Center) P30CA014520-UWU.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) F31CA271826U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P50CA180995U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA257446U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA275193U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) T32CA009560U.S. Department of Veterans Affairs (Department of Veterans Affairs) CX002479
6 · The paper itself

Abstract

FOXA1 is a prostate lineage-specifying transcription factor that is frequently dysregulated or mutated in prostate cancer (PCa). While FOXA1 has been reported to exhibit both PCa-promoting and -inhibitory functions, its role within an immune-proficient PCa context remains unclear. Here, we show that prostate-specific deletion of Foxa1 in Pten-deficient mice drives tumor progression by reprogramming luminal PCa cells toward a basal/squamous-like state and promoting an immunosuppressive tumor microenvironment. Histological and transcriptomic analyses reveal aggressive tumors with extensive basal/squamous features, a reactive stroma, and disorganized tissue architecture. Mechanistically, FOXA1 directly represses basal/squamous and inflammatory genes, which become activated upon its depletion. This is accompanied by an accumulation of immunosuppressive myeloid cells, dysfunctional T cells, and immunosuppressive cytokine signaling. Together, these findings demonstrate a tumor-suppressive role for FOXA1 as an enforcer of luminal identity, such that its loss drives basal/squamous de-differentiation, inflammatory response, and immunosuppression.

Indexed as

Hepatocyte Nuclear Factor 3-alphaProstatic NeoplasmsTumor MicroenvironmentAnimalsCell DifferentiationCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMiceMice, KnockoutPTEN PhosphohydrolaseFOXA1 protein, humanFoxa1 protein, mouseHepatocyte Nuclear Factor 3-alphaPTEN PhosphohydrolasePten protein, mouse

Identifiers

PMID41904157
PMCPMC13195071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.